08:46 AM EDT, 09/04/2025 (MT Newswires) -- Guardant Health ( GH ) said Thursday its updated Shield V2 algorithm for colorectal cancer screening met primary endpoints and showed 84% sensitivity and 90% specificity, with 62% sensitivity in detecting stage I CRC.

The results were validated in an expanded group from the Eclipse study, which enrolled more than 20,000 people, the company said.

The algorithm achieved 100% sensitivity for stage II and IV cancers and 96% for stage III, while detection of advanced adenomas was only 13%, Guardant said.

The company also said the National Comprehensive Cancer Network recently added Shield as the first US Food and Drug Administration-approved blood test for primary colorectal cancer screening.

Shares of the company were down by more than 7.8% in recent Thursday premarket activity.